stockrow
Saturday 7 November 2026
Export AIDX’s income statement to Excel — free account
20/20 Biolabs Inc.
AIDX Healthcare Medical Devices
20/20 Biolabs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 16.7% from fiscal 2024.
0.20
0.01
+5.26%
Follow AIDX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 2 | 2 | 2 | +16.7% | 3 | 6 | 9 | +63.2% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 20.56 | 29.56 | 32.06 | +9.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (6) | (4) | (5) | (32.7%) | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (316.82) | (182.82) | (243.30) | +134.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (6) | (4) | (8) | (32.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.37 | 0.41 | 0.20 | +13.6% | |||||
| Earnings | — | — | — | — | — | — | — | — | (1.16) | (0.76) | (0.87) | (34.3%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (0.54) | (0.39) | (0.40) | (28.1%) | ||||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.54) | (0.39) | (0.40) | (28.1%) | ||||||
| Book value | — | — | — | — | — | — | — | — | 0.31 | 0.00 | 0.29 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 5 | 5 | 7 | +2.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.99 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 1.33 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | (0.67) | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (20.70) | (20.70) | 0.34 | (20.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (3) | (2) | (4) | (26.1%) | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (3) | (2) | (4) | (26.1%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 1 | (1) | 3 | n/m | |||||
| Net debt | — | — | — | — | — | — | — | — | (2) | 0 | (5) | (81.4%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 2 | 0 | 3 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (96.84) | (211.61) | (96.8) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (537.07) | 0.00 | (537.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 14 | 14 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.13 | 0.15 | — | +16.7% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
20/20 Biolabs Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VVOS Vivos Therapeutics, Inc. | $3.5M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| AMIX Autonomix Medical, Inc. | $3.0M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | Compare |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AIDX 20/20 Biolabs Inc. | $2.5M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | |
| BJDX Bluejay Diagnostics, Inc. | $2.5M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.4M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.4M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $2.4M | — | — | +14.14% | — | +10.16% | 35.06% | (76.46%) |